Skip to main content

Table 1 Demographic/baseline characteristics: by presence/absence of pain at baseline (as rated by Likert pain scale)

From: Rotigotine transdermal system and evaluation of pain in patients with Parkinson’s disease: a post hocanalysis of the RECOVER study

 

‘No’ pain (n = 80) (pain score 0)

‘Any’ pain (n = 187)

(pain score ≥1)

‘Mild’ pain (n = 87)

‘Moderate-to-severe’ pain (n = 100)

  

(pain score 1–3)

(pain score ≥4)

Age, years

66.4 ± 9.3 (37–86)

63.8 ± 9.8 (37–85); (p = 0.048)

  

63.1 ± 10.4 (37–85); (p = 0.032)

64.5 ± 9.3 (40–83); (p = 0.175)

Female

23 (29)

69 (37); (p = 0.199)

  

23 (26); (p = 0.738)

46 (46); (p = 0.018)

Time since diagnosis, years

4.7 ± 4.4 (0.0–22.9)

4.9 ± 4.4 (0.0–25.6); (p = 0.820)

  

4.5 ± 3.8 (0.0–17.2); (p = 0.765)

5.1 ± 4.9 (0.0–25.6); (p = 0.555)

Taking levodopa (advanced PD)

62 (78)

156 (83); (p = 0.252)

  

70 (80); (p = 0.639)

86 (86); (p = 0.138)

UPDRS III total score

28.3 ± 11.1

31.3 ± 13.5; (p = 0.075)

  

29.2 ± 11.9; (p = 0.621)

33.2 ± 14.5; (p = 0.013)

PDSS-2 total score

16.0 ± 7.8

21.2 ± 9.8; (p <0.0001)

  

18.6 ± 9.2; (p = 0.048)

23.5 ± 9.8; (p <0.0001)

  1. Data are mean ± SD (range) or number of patients (%). Data are presented for the FAS.
  2. P values (t-test for continuous data, Chi-square test for categorical data; exploratory analyses) are reported for patients with ‘Any’ pain, ‘Mild’ pain, and ‘Moderate-to-severe’ pain vs patients with ‘No’ pain at baseline (assessed by the Likert pain scale).
  3. FAS: full analysis set; PD: Parkinson’s disease; PDSS-2: Parkinson’s Disease Sleep Scale; SD: standard deviation; UPDRS III: Unified Parkinson’s Disease Rating Scale.
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us